ESPR (Esperion Therapeutics) EBIT per Share : $0.04 (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Esperion Therapeutics EBIT per Share?

Esperion Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Esperion Therapeutics's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Esperion Therapeutics was 46.00% per year. The lowest was -49.90% per year. And the median was 3.55% per year.

ESPR's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Esperion Therapeutics's EBIT for the three months ended in Dec. 2024 was $-4.9 Mil.

Esperion Therapeutics EBIT per Share Historical Data

The historical data trend for Esperion Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics EBIT per Share Chart

Esperion Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-4.40

-7.71

-2.66

-1.46

0.04

Esperion Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.37	0.40	-0.26	-0.07	-0.03

Esperion Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Esperion Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	7.506	/	187.182
=	0.04

Esperion Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.896	/	195.628
=	-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04

Esperion Therapeutics (NAS:ESPR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Esperion Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0IIM:UK 0ET:Germany 0ET:Germany

Address

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108

Website

https://www.esperion.com

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Executives

Benjamin Halladay	officer: Chief Financial Officer	ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Sheldon L. Koenig	officer: Chief Operating Officer	C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Eric Warren	officer: Chief Commercial Officer	3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joanne M. Foody	officer: Chief Medical Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli	director	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Benjamin Looker	officer: General Counsel	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben	director, officer: Pres & Chief Executive Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall	officer: Chief Development Officer	C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram	officer: Chief Financial Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo	director, 10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121